B. Riley Keeps Buy on 4D Molecular After EyePoint’s Phase 3 Miss
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.
/ 185 items
#XY Analyst Up/Down↓
Jefferies Upgrades Minerva Neurosciences to Buy on Clearer FDA Path for Roluperidone
Minerva gained analyst support as its schizophrenia drug advances in Phase 3, backed by new funding and a clearer FDA path.
Capricor Soars After Cantor Upgrade as FDA Path for Deramiocel Becomes Clearer
Analyst upgrade sends Capricor shares higher after company outlines BLA amendment path for deramiocel focused on upper-limb function.
Morgan Stanley Starts Coverage of Achieve Life Sciences at Overweight with $13 Price Target
Achieve's smoking-cessation drug impressed analysts with strong trial results, putting the company on track for possible FDA approval in 2027.
Berenberg Downgrades Novo Nordisk to Hold as ‘Battle of the Pills’ Heats Up
Novo Nordisk faces tougher H2. Berenberg downgrades to Hold on rising rivalry with Lilly’s Foundayo.
Zymeworks: Citi Flags Major Upside Catalyst Ahead of August 25 FDA Decision
Citi places Zymeworks on 90-day upside watch with Buy rating and $37 target ahead of the Aug 25 FDA decision on zanidatamab for HER2+ GEA.